About us

At Atransen Pharma, we are dedicated to transforming the future of cancer treatment through innovative drug discovery. As a biotechnology startup, our mission is to develop groundbreaking therapies that bring new hope to patients and their families. Central to this mission is our focus on LAT1 inhibitors, a novel approach to targeting cancer cells.Our research is built upon the pioneering work of Professor Yoshikatsu Kanai from Osaka University, a world-renowned leader in the study of amino acid transporters. His groundbreaking discoveries form the foundation of our work, particularly in targeting LAT1 (L-type Amino Acid Transporter 1). LAT1 plays a crucial role in cancer cell metabolism, facilitating the uptake of essential amino acids required for their rapid growth. By inhibiting LAT1, we aim to disrupt this critical process, offering a new therapeutic avenue for cancer treatment.At Atransen Pharma, we are also committed to advancing the field of transporter-focused drug discovery. Transporters are essential for the absorption, distribution, metabolism, and excretion of drugs in the body. By targeting specific transporters like LAT1, we strive to develop safer and more effective treatments that address the unique needs of cancer patients.Cancer remains a profound challenge affecting millions of lives worldwide. By leveraging the latest scientific insights, we are working to develop LAT1 inhibitors that provide more effective treatment options with fewer side effects. We believe this novel approach will not only improve patients’ quality of life but also pave the way for a new era in cancer therapy.We are confident that our LAT1 inhibitors will bring transformative innovation to cancer treatment and deliver new hope to patients in need. As we continue to advance our mission, we deeply appreciate your support and guidance in our journey.Thank you for joining us in creating a brighter future for cancer care.Sincerely,

Tomoyuki AsanoCEO,
Atransen Pharma